Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Sunday. The brokerage issued a hold rating on the medical research company’s stock.

Several other brokerages also recently issued reports on CTSO. HC Wainwright reaffirmed a neutral rating and set a $1.00 price target on shares of Cytosorbents in a report on Tuesday, May 7th. B. Riley restated a buy rating and set a $3.00 price objective on shares of Cytosorbents in a research report on Wednesday, May 15th.

Cytosorbents Price Performance

Shares of CTSO opened at $1.03 on Friday. The company has a current ratio of 1.49, a quick ratio of 1.21 and a debt-to-equity ratio of 0.10. The company’s fifty day simple moving average is $0.90 and its 200 day simple moving average is $0.92. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $3.85. The company has a market cap of $55.67 million, a price-to-earnings ratio of -1.74 and a beta of 0.58.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12). Cytosorbents had a negative net margin of 75.07% and a negative return on equity of 129.89%. The company had revenue of $9.79 million for the quarter, compared to analyst estimates of $9.78 million. During the same period in the previous year, the business earned ($0.17) EPS. On average, research analysts forecast that Cytosorbents will post -0.36 earnings per share for the current fiscal year.

Institutional Trading of Cytosorbents

A number of institutional investors have recently bought and sold shares of the business. Key Client Fiduciary Advisors LLC raised its position in shares of Cytosorbents by 188.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after buying an additional 22,557 shares in the last quarter. Raymond James & Associates acquired a new position in Cytosorbents in the 4th quarter valued at $56,000. CM Management LLC raised its holdings in Cytosorbents by 98.8% in the 1st quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock valued at $784,000 after acquiring an additional 410,000 shares in the last quarter. Sargent Investment Group LLC lifted its position in shares of Cytosorbents by 4.1% during the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after acquiring an additional 51,699 shares during the period. Finally, Neuberger Berman Group LLC grew its holdings in shares of Cytosorbents by 19.9% during the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after purchasing an additional 299,103 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.